-
1
-
-
0037460729
-
Cystic fibrosis
-
Ratjen F, Doring G. Cystic fibrosis. Lancet 2003. 361[9358]: 681-9.
-
(2003)
Lancet
, vol.361
, Issue.9358
, pp. 681-689
-
-
Ratjen, F.1
Doring, G.2
-
2
-
-
66849089934
-
Cystic fibrosis: Pathogenesis and future treatment strategies
-
Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009. 54[5]: 595-605.
-
(2009)
Respir Care
, vol.54
, Issue.5
, pp. 595-605
-
-
Ratjen, F.A.1
-
3
-
-
34848821636
-
New pulmonary therapies for cystic fibrosis
-
Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007. 13[6]: 541-6.
-
(2007)
Curr Opin Pulm Med
, vol.13
, Issue.6
, pp. 541-546
-
-
Ratjen, F.1
-
5
-
-
84856408603
-
Modifier gene studies to identify new therapeutic targets in cystic fibrosis
-
Dorfman R. Modifier gene studies to identify new therapeutic targets in cystic fibrosis. Curr Pharm Des 2012; 18(5): 674-82.
-
(2012)
Curr Pharm Des
, vol.18
, Issue.5
, pp. 674-682
-
-
Dorfman, R.1
-
6
-
-
0031851457
-
Glutathione permeability of CFTR
-
Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998; 275[1 Pt 1]: C323-6.
-
(1998)
Am J Physiol
, vol.275
, Issue.1 Pt 1
-
-
Linsdell, P.1
Hanrahan, J.W.2
-
7
-
-
0036305756
-
Mucociliary transport and cough in humans
-
Foster WM. Mucociliary transport and cough in humans. Pulm Pharmacol Ther 2002; 15[3]: 277-82.
-
(2002)
Pulm Pharmacol Ther
, vol.15
, Issue.3
, pp. 277-282
-
-
Foster, W.M.1
-
8
-
-
34047166052
-
Airway surface dehydration in cystic fibrosis: Pathogenesis and therapy
-
Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007; 58: 157-70.
-
(2007)
Annu Rev Med
, vol.58
, pp. 157-170
-
-
Boucher, R.C.1
-
9
-
-
33645964965
-
Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress
-
Tarran R, Button B, Boucher RC. Regulation of normal and cystic fibrosis airway surface liquid volume by phasic shear stress. Annu Rev Physiol 2006; 68: 543-61.
-
(2006)
Annu Rev Physiol
, vol.68
, pp. 543-561
-
-
Tarran, R.1
Button, B.2
Boucher, R.C.3
-
10
-
-
0036167851
-
Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients
-
Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002; 109[3]: 317-25.
-
(2002)
J Clin Invest
, vol.109
, Issue.3
, pp. 317-325
-
-
Worlitzsch, D.1
Tarran, R.2
Ulrich, M.3
-
11
-
-
84856488316
-
Progress in gene and cell therapy for cystic fibrosis lung disease
-
Griesenbach U, Eric WFW. Progress in gene and cell therapy for cystic fibrosis lung disease. Curr Pharm Des 2012; 18(5): 642-62.
-
(2012)
Curr Pharm Des
, vol.18
, Issue.5
, pp. 642-662
-
-
Griesenbach, U.1
Eric, W.F.W.2
-
12
-
-
0026781952
-
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
-
Denning GM, Anderson MP, Amara JF, et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358[6389]: 761-4.
-
(1992)
Nature
, vol.358
, Issue.6389
, pp. 761-764
-
-
Denning, G.M.1
Anderson, M.P.2
Amara, J.F.3
-
13
-
-
43449091135
-
Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse
-
Buvoli M, Buvoli A, Leinwand LA. Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse. PLoS One 2007; 2[5]: e427.
-
(2007)
PLoS One
, vol.2
, Issue.5
-
-
Buvoli, M.1
Buvoli, A.2
Leinwand, L.A.3
-
14
-
-
28644433645
-
Mild cystic fibrosis revealed by persistent hyponatremia during the French 2003 heat wave, associated with the S1455X C-terminus CFTR mutation
-
Epaud R, Girodon E, Corvol H, et al. Mild cystic fibrosis revealed by persistent hyponatremia during the French 2003 heat wave, associated with the S1455X C-terminus CFTR mutation. Clin Genet 2005; 68[6]: 552-3.
-
(2005)
Clin Genet
, vol.68
, Issue.6
, pp. 552-553
-
-
Epaud, R.1
Girodon, E.2
Corvol, H.3
-
15
-
-
0141863491
-
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations
-
Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349[15]: 1433-41.
-
(2003)
N Engl J Med
, vol.349
, Issue.15
, pp. 1433-1441
-
-
Wilschanski, M.1
Yahav, Y.2
Yaacov, Y.3
-
16
-
-
34347224756
-
No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations
-
Clancy JP, Rowe SM, Bebok Z, et.al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007; 37[1]: 57-66.
-
(2007)
Am J Respir Cell Mol Biol
, vol.37
, Issue.1
, pp. 57-66
-
-
Clancy, J.P.1
Rowe, S.M.2
-
17
-
-
34247588271
-
PTC124 targets genetic disorders caused by nonsense mutations
-
Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447[7140]: 87-91.
-
(2007)
Nature
, vol.447
, Issue.7140
, pp. 87-91
-
-
Welch, E.M.1
Barton, E.R.2
Zhuo, J.3
-
18
-
-
33947529670
-
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers
-
Hirawat S, Welch EM, Elfring GL, et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 2007; 47[4]: 430-44.
-
(2007)
J Clin Pharmacol
, vol.47
, Issue.4
, pp. 430-444
-
-
Hirawat, S.1
Welch, E.M.2
Elfring, G.L.3
-
19
-
-
33847360602
-
Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin
-
Linde L, Boelz S, Nissim-Rafinia M, et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 2007; 117[3]: 683-92.
-
(2007)
J Clin Invest
, vol.117
, Issue.3
, pp. 683-692
-
-
Linde, L.1
Boelz, S.2
Nissim-Rafinia, M.3
-
20
-
-
34247200483
-
In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: A pilot study
-
Sermet-Gaudelus I, Renouil M, Fajac A, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007; 5: 5.
-
(2007)
BMC Med
, vol.5
, pp. 5
-
-
Sermet-Gaudelus, I.1
Renouil, M.2
Fajac, A.3
-
21
-
-
50149098401
-
Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: A prospective phase II trial
-
Kerem E, Hirawat S, Armoni S, et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 2008; 372[9640]: 719-27.
-
(2008)
Lancet
, vol.372
, Issue.9640
, pp. 719-727
-
-
Kerem, E.1
Hirawat, S.2
Armoni, S.3
-
22
-
-
78349290383
-
Ataluren [PTC124] induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis
-
Sermet-Gaudelus I, Boeck KD, Casimir GJ, et al. Ataluren [PTC124] induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med 2010; 182[10]: 1262-72.
-
(2010)
Am J Respir Crit Care Med
, vol.182
, Issue.10
, pp. 1262-1272
-
-
Sermet-Gaudelus, I.1
Boeck, K.D.2
Casimir, G.J.3
-
23
-
-
79960187095
-
Chronic ataluren [PTC124] treatment of nonsense mutation cystic fibrosis
-
Wilschanski M, Miller LL, Shoseyov D, et al. Chronic ataluren [PTC124] treatment of nonsense mutation cystic fibrosis. Eur Respir J 2011; 38(1): 59-69.
-
(2011)
Eur Respir J
, vol.38
, Issue.1
, pp. 59-69
-
-
Wilschanski, M.1
Miller, L.L.2
Shoseyov, D.3
-
24
-
-
84856499552
-
-
NCT00803205
-
www.clinicaltrials.gov: NCT00803205.
-
-
-
-
25
-
-
0025242929
-
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
-
Cheng S, Gregory R, Marshall J, et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 1990; 63: 827-834.
-
(1990)
Cell
, vol.63
, pp. 827-834
-
-
Cheng, S.1
Gregory, R.2
Marshall, J.3
-
26
-
-
50649123290
-
CFTR function and prospects for therapy
-
Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-26.
-
(2008)
Annu Rev Biochem
, vol.77
, pp. 701-726
-
-
Riordan, J.R.1
-
27
-
-
77956237958
-
A chemical corrector modifies the channel function of F508del-CFTR
-
Epub
-
Kim Chiaw P, Wellhauser L, Huan LJ, et al. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 2010; 78[3]: 411-8. Epub.
-
(2010)
Mol Pharmacol
, vol.78
, Issue.3
, pp. 411-418
-
-
Kim, C.P.1
Wellhauser, L.2
Huan, L.J.3
-
28
-
-
77953133544
-
Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin [G418] with enhanced suppression of diseases-causing nonsense mutations
-
Nudelman I, Glikin D, Smolkin B, et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin [G418] with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 2010; 18[11]: 3735-46.
-
(2010)
Bioorg Med Chem
, vol.18
, Issue.11
, pp. 3735-3746
-
-
Nudelman, I.1
Glikin, D.2
Smolkin, B.3
-
29
-
-
0037088577
-
Genistein restores functional interactions between Delta F508-CFTR and ENaC in Xenopus oocytes
-
Suaud L, Li J, Jiang Q, et al. Genistein restores functional interactions between Delta F508-CFTR and ENaC in Xenopus oocytes. J Biol Chem 2002; 277[11]: 8928-33.
-
(2002)
J Biol Chem
, vol.277
, Issue.11
, pp. 8928-8933
-
-
Suaud, L.1
Li, J.2
Jiang, Q.3
-
30
-
-
0036665609
-
Evidence of CFTR function in cystic fibrosis after systemic administration of 4- phenylbutyrate
-
Zeitlin P, Diener-West M, Rubenstein R, et al. Evidence of CFTR function in cystic fibrosis after systemic administration of 4- phenylbutyrate. Mol Ther 2002; 6: 119-126.
-
(2002)
Mol Ther
, vol.6
, pp. 119-126
-
-
Zeitlin, P.1
Diener-West, M.2
Rubenstein, R.3
-
31
-
-
11144355340
-
Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects
-
Egan M, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-602.
-
(2004)
Science
, vol.304
, pp. 600-602
-
-
Egan, M.1
Pearson, M.2
Weiner, S.A.3
-
32
-
-
6044268094
-
Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells
-
Dragomir A, Bjorstad J, Hjelte L, et al. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004; 322: 447-451.
-
(2004)
Biochem Biophys Res Commun
, vol.322
, pp. 447-451
-
-
Dragomir, A.1
Bjorstad, J.2
Hjelte, L.3
-
33
-
-
4644360693
-
Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models
-
Song Y, Sonawane N, Salinas D, et al. Evidence against the rescue of defective DeltaF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 2004; 279: 40629-40623.
-
(2004)
J Biol Chem
, vol.279
, pp. 40623-40629
-
-
Song, Y.1
Sonawane, N.2
Salinas, D.3
-
34
-
-
33947543364
-
Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains
-
Wang W, Bernard K, Li G, et al. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 2006; 282: 4533-4544.
-
(2006)
J Biol Chem
, vol.282
, pp. 4533-4544
-
-
Wang, W.1
Bernard, K.2
Li, G.3
-
35
-
-
24644464284
-
Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by highthroughput screening
-
Pedemonte N, Lukacs G, Du K, et al. Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by highthroughput screening. J Clin Invest 2001; 115: 2564-2571.
-
(2001)
J Clin Invest
, vol.115
, pp. 2564-2571
-
-
Pedemonte, N.1
Lukacs, G.2
Du, K.3
-
36
-
-
33744831154
-
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules
-
Van Goor F, Straley K, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Cell Physiol 2006; 290: L1117-L1130.
-
(2006)
Am J Physiol Cell Physiol
, vol.290
-
-
van Goor, F.1
Straley, K.2
Cao, D.3
-
37
-
-
84856507079
-
-
http://investor.shareholder.com/vrtx/releasedetail.cfm?ReleaseID=442429
-
-
-
-
38
-
-
0027380236
-
The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells
-
Lukacs GL, Chang XB, Bear C, et al The delta F508 mutation decreases the stability of cystic fibrosis transmembrane conductance regulator in the plasma membrane. Determination of functional half-lives on transfected cells. J Biol Chem 1993; 268[29]: 21592-8.
-
(1993)
J Biol Chem
, vol.268
, Issue.29
, pp. 21592-21598
-
-
Lukacs, G.L.1
Chang, X.B.2
Bear, C.3
-
39
-
-
78549279173
-
Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation
-
Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363[21]: 1991-2003.
-
(2010)
N Engl J Med
, vol.363
, Issue.21
, pp. 1991-2003
-
-
Accurso, F.J.1
Rowe, S.M.2
Clancy, J.P.3
-
40
-
-
80455162465
-
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation
-
VX08-770-102 Study Group
-
Ramsey BW, Davies J, McElvaney NG, et al. VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011; 365(18): 1663-72.
-
(2011)
N Engl J Med
, vol.365
, Issue.18
, pp. 1663-1672
-
-
Ramsey, B.W.1
Davies, J.2
McElvaney, N.G.3
-
41
-
-
77953122968
-
DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers
-
Rowe SM, Pyle LC, Jurkevante A, et al. DeltaF508 CFTR processing correction and activity in polarized airway and non-airway cell monolayers. Pulm Pharmacol Ther 2010; 23[4]: 268-78.
-
(2010)
Pulm Pharmacol Ther
, vol.23
, Issue.4
, pp. 268-278
-
-
Rowe, S.M.1
Pyle, L.C.2
Jurkevante, A.3
-
42
-
-
0025874599
-
Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis
-
Knowles M, Clarke L, Boucher R. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325: 533-538.
-
(1991)
N Engl J Med
, vol.325
, pp. 533-538
-
-
Knowles, M.1
Clarke, L.2
Boucher, R.3
-
43
-
-
0035880177
-
Effect of aerosolized uridine 5'- triphosphate on mucociliary clearance in mild chronic bronchitis
-
Bennett W, Zeman K, Foy C, et al. Effect of aerosolized uridine 5'- triphosphate on mucociliary clearance in mild chronic bronchitis. Am J Respir Crit Care Med 2001; 164: 302-306.
-
(2001)
Am J Respir Crit Care Med
, vol.164
, pp. 302-306
-
-
Bennett, W.1
Zeman, K.2
Foy, C.3
-
44
-
-
20144363443
-
Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: Results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis
-
Deterding R, Retsch-Bogart G, Milgram L, et al. Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005; 39: 339-348.
-
(2005)
Pediatr Pulmonol
, vol.39
, pp. 339-348
-
-
Deterding, R.1
Retsch-Bogart, G.2
Milgram, L.3
-
45
-
-
34547949974
-
Phase Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis
-
Deterding R, Lavange L, Engels J, et al. Phase Randomized Safety and Efficacy Trial of Nebulized Denufosol Tetrasodium in Cystic Fibrosis. Am J Respir Crit Care Med 2007; 176[4]: 362-9
-
(2007)
Am J Respir Crit Care Med
, vol.176
, Issue.4
, pp. 362-369
-
-
Deterding, R.1
Lavange, L.2
Engels, J.3
-
46
-
-
79952211206
-
Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function
-
Accurso FJ, Moss RB, Wilmott RW, et al. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med 2011; 183[5]: 627-34.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, Issue.5
, pp. 627-634
-
-
Accurso, F.J.1
Moss, R.B.2
Wilmott, R.W.3
-
47
-
-
57149104917
-
Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice
-
Zhou Z, Treis D, Schubert SC, et al. Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 2008; 178[12]: 1245-56.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.12
, pp. 1245-1256
-
-
Zhou, Z.1
Treis, D.2
Schubert, S.C.3
-
48
-
-
0037324136
-
Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice
-
McNulty MJ, Hutabarat RH, Findlay JW, et al. Pharmacokinetics and tissue distribution of the nonadecapeptide Moli1901 in rats and mice. Xenobiotica 2003; 33[2]: 197-210
-
(2003)
Xenobiotica
, vol.33
, Issue.2
, pp. 197-210
-
-
McNulty, M.J.1
Hutabarat, R.H.2
Findlay, J.W.3
-
49
-
-
20644458109
-
Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation
-
Rickert DE, Dingley K, Ubick E, et al. Determination of the tissue distribution and excretion by accelerator mass spectrometry of the nonadecapeptide 14C-Moli1901 in beagle dogs after intratracheal instillation. Chem Biol Interact 2005; 155[1-2]: 55-61.
-
(2005)
Chem Biol Interact
, vol.155
, Issue.1-2
, pp. 55-61
-
-
Rickert, D.E.1
Dingley, K.2
Ubick, E.3
-
50
-
-
1642493889
-
A phase I trial of intranasal Moli1901 for cystic fibrosis
-
Zeitlin P, Boyle M, Guggino W. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2005; 25: 143-149.
-
(2005)
Chest
, vol.25
, pp. 143-149
-
-
Zeitlin, P.1
Boyle, M.2
Guggino, W.3
-
52
-
-
84856501598
-
-
www.clinicaltrials.gov/ct2/show/NCT00671736.
-
-
-
-
53
-
-
33750842131
-
Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis
-
Wang X, Venable J, LaPointe P, et al. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 2006; 127[4]: 803-15.
-
(2006)
Cell
, vol.127
, Issue.4
, pp. 803-815
-
-
Wang, X.1
Venable, J.2
Lapointe, P.3
-
54
-
-
0033581885
-
Activation of the epithelial Na+ channel [ENaC] requires CFTR Cl-channel function
-
Reddy M, Light MJ, Quinton P. Activation of the epithelial Na+ channel [ENaC] requires CFTR Cl-channel function. Nature 1999; 402: 301-304.
-
(1999)
Nature
, vol.402
, pp. 301-304
-
-
Reddy, M.1
Light, M.J.2
Quinton, P.3
-
55
-
-
2442718786
-
Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice
-
Mall M, Grubb B, Harkema J, et al. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 2004; 10: 487-493.
-
(2004)
Nat Med
, vol.10
, pp. 487-493
-
-
Mall, M.1
Grubb, B.2
Harkema, J.3
-
56
-
-
77957592219
-
Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells
-
Prulière-Escabasse V, Clerici C, Vuagniaux G, et al. Effect of neutrophil elastase and its inhibitor EPI-hNE4 on transepithelial sodium transport across normal and cystic fibrosis human nasal epithelial cells. Respir Res 2010; 11: 141.
-
(2010)
Respir Res
, vol.11
, pp. 141
-
-
Prulière-Escabasse, V.1
Clerici, C.2
Vuagniaux, G.3
-
57
-
-
0027520191
-
Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum
-
Tomkiewicz RP, App EM, Zayas JG, et al. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. Am Rev Respir Dis 1993; 148[4 Pt 1]: 1002-7.
-
(1993)
Am Rev Respir Dis
, vol.148
, Issue.4 Pt 1
, pp. 1002-1007
-
-
Tomkiewicz, R.P.1
App, E.M.2
Zayas, J.G.3
-
58
-
-
0027486593
-
No added benefit from nebulized amiloride in patients with cystic fibrosis
-
Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6[9]: 1243-8.
-
(1993)
Eur Respir J
, vol.6
, Issue.9
, pp. 1243-1248
-
-
Graham, A.1
Hasani, A.2
Alton, E.W.3
-
59
-
-
0028787073
-
Nebulised amiloride in respiratory exacerbations of cystic fibrosis: A randomised controlled trial
-
Bowler IM, Kelman B, Worthington D, et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995; 73[5]: 427-30.
-
(1995)
Arch Dis Child
, vol.73
, Issue.5
, pp. 427-430
-
-
Bowler, I.M.1
Kelman, B.2
Worthington, D.3
-
60
-
-
0034047238
-
French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group
-
Pons G, Marchand MC, d'Athis P, et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 2000; 30[1]: 25-31.
-
(2000)
Pediatr Pulmonol
, vol.30
, Issue.1
, pp. 25-31
-
-
Pons, G.1
Marchand, M.C.2
D'Athis, P.3
-
61
-
-
57149094665
-
Amiloride: Still a viable treatment option in cystic fibrosis?
-
Ratjen F, Bush A. Amiloride: still a viable treatment option in cystic fibrosis? Am J Respir Crit Care Med 2008; 178[12]: 1191-2.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.12
, pp. 1191-1192
-
-
Ratjen, F.1
Bush, A.2
-
63
-
-
30944452384
-
Mucus clearance and lung function in cystic fibrosis with hypertonic saline
-
Donaldson S, Bennett W, Zeman K, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 250.
-
(2006)
N Engl J Med
, vol.354
, pp. 250
-
-
Donaldson, S.1
Bennett, W.2
Zeman, K.3
-
64
-
-
33748744717
-
Hypertonic saline therapy in cystic fibrosis: Evidence against the proposed mechanism involving aquaporins
-
Levin M, Sullivan S, Nielson D, et al. Hypertonic saline therapy in cystic fibrosis: Evidence against the proposed mechanism involving aquaporins. J Biol Chem 2006; 281: 25803-12.
-
(2006)
J Biol Chem
, vol.281
, pp. 25803-25812
-
-
Levin, M.1
Sullivan, S.2
Nielson, D.3
-
65
-
-
10044235073
-
Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease
-
Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004; 311[3]: 929-38.
-
(2004)
J Pharmacol Exp Ther
, vol.311
, Issue.3
, pp. 929-938
-
-
Hirsh, A.J.1
Sabater, J.R.2
Zamurs, A.3
-
66
-
-
33745838632
-
Design, synthesis, and structureactivity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: Drugs for cystic fibrosis and chronic bronchitis
-
Hirsh A, Molino B, Zhang J, et al. Design, synthesis, and structureactivity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem 2006; 49: 4098-4115.
-
(2006)
J Med Chem
, vol.49
, pp. 4098-4115
-
-
Hirsh, A.1
Molino, B.2
Zhang, J.3
-
67
-
-
30944452609
-
Restoring Airway Surface Liquid in Cystic Fibrosis
-
Ratjen F. Restoring Airway Surface Liquid in Cystic Fibrosis. N Engl J Med 2006; 354: 291-293.
-
(2006)
N Engl J Med
, vol.354
, pp. 291-293
-
-
Ratjen, F.1
-
68
-
-
0030784262
-
Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis
-
Robinson M, Hemming A, Regnis J, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997; 52: 900-903.
-
(1997)
Thorax
, vol.52
, pp. 900-903
-
-
Robinson, M.1
Hemming, A.2
Regnis, J.3
-
69
-
-
0035922668
-
Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: A randomised trial
-
Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001; 358[9290]: 1316-21.
-
(2001)
Lancet
, vol.358
, Issue.9290
, pp. 1316-1321
-
-
Suri, R.1
Metcalfe, C.2
Lees, B.3
-
70
-
-
0036123981
-
Hypertonic saline and recombinant human DNase: A randomised cross-over pilot study in patients with cystic fibrosis
-
Ballmann M, von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros 2002; 1[1]: 35-7.
-
(2002)
J Cyst Fibros
, vol.1
, Issue.1
, pp. 35-37
-
-
Ballmann, M.1
von der Hardt, H.2
-
72
-
-
30944466084
-
National Hypertonic Saline in Cystic Fibrosis [NHSCF] Study Group. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis
-
Elkins M, Robinson M, Rose B, et al. National Hypertonic Saline in Cystic Fibrosis [NHSCF] Study Group. A controlled trial of longterm inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-240.
-
(2006)
N Engl J Med
, vol.354
, pp. 229-240
-
-
Elkins, M.1
Robinson, M.2
Rose, B.3
-
74
-
-
77951988740
-
Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function
-
Amin R, Subbarao P, Jabar A, et al. Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function. Thorax 2010; 65[5]: 379-83.
-
(2010)
Thorax
, vol.65
, Issue.5
, pp. 379-383
-
-
Amin, R.1
Subbarao, P.2
Jabar, A.3
-
75
-
-
34247880282
-
Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis
-
Subbarao P, Balkovec S, Solomon M, et al. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42: 471-476.
-
(2007)
Pediatr Pulmonol
, vol.42
, pp. 471-476
-
-
Subbarao, P.1
Balkovec, S.2
Solomon, M.3
-
76
-
-
57349158832
-
Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis
-
Dellon EP, Donaldson SH, Johnson R, et al. Safety and tolerability of inhaled hypertonic saline in young children with cystic fibrosis. Pediatr Pulmonol 2008; 43[11]: 1100-6.
-
(2008)
Pediatr Pulmonol
, vol.43
, Issue.11
, pp. 1100-1106
-
-
Dellon, E.P.1
Donaldson, S.H.2
Johnson, R.3
-
77
-
-
79959828264
-
Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: Short-term tolerability, adherence, and safety
-
Rosenfeld M, Davis S, Brumback L, et al. Inhaled hypertonic saline in infants and toddlers with cystic fibrosis: short-term tolerability, adherence, and safety. Pediatr Pulmonol 2011; 46(7): 666-71.
-
(2011)
Pediatr Pulmonol
, vol.46
, Issue.7
, pp. 666-671
-
-
Rosenfeld, M.1
Davis, S.2
Brumback, L.3
-
78
-
-
84856507081
-
-
NCT00709280
-
www.clinicaltrials.gov:: NCT00709280
-
-
-
-
79
-
-
57349176546
-
Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis
-
Minasian C, Wallis C, Metcalfe C, et al. Bronchial provocation testing with dry powder mannitol in children with cystic fibrosis. Pediatr Pulmonol 2008; 43[11]: 1078-84.
-
(2008)
Pediatr Pulmonol
, vol.43
, Issue.11
, pp. 1078-1084
-
-
Minasian, C.1
Wallis, C.2
Metcalfe, C.3
-
80
-
-
77950787429
-
Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis
-
Daviskas E, Anderson SD, Jaques A, et al. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010; 137[4]: 861-8.
-
(2010)
Chest
, vol.137
, Issue.4
, pp. 861-868
-
-
Daviskas, E.1
Anderson, S.D.2
Jaques, A.3
-
81
-
-
78651452280
-
Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial
-
Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J Cyst Fibros 2011; 10[1]: 1-8.
-
(2011)
J Cyst Fibros
, vol.10
, Issue.1
, pp. 1-8
-
-
Teper, A.1
Jaques, A.2
Charlton, B.3
-
82
-
-
44649166466
-
Inhaled mannitol improves lung function in cystic fibrosis
-
Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133[6]: 1388-96.
-
(2008)
Chest
, vol.133
, Issue.6
, pp. 1388-1396
-
-
Jaques, A.1
Daviskas, E.2
Turton, J.A.3
-
83
-
-
80355127141
-
Inhaled dry powder mannitol in cystic fibrosis: An efficacy and safety study
-
Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38(5): 1071-80.
-
(2011)
Eur Respir J
, vol.38
, Issue.5
, pp. 1071-1080
-
-
Bilton, D.1
Robinson, P.2
Cooper, P.3
-
84
-
-
33644620356
-
Respiratory tract mucin genes and mucin glycoproteins in health and disease
-
Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006; 86[1]: 245-28.
-
(2006)
Physiol Rev
, vol.86
, Issue.1
, pp. 245-248
-
-
Rose, M.C.1
Voynow, J.A.2
-
85
-
-
0001609666
-
The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine
-
Sheffner AL, Medler EM, Jacobs LW, et al. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am Rev Respir Dis 1964; 90: 721-9.
-
(1964)
Am Rev Respir Dis
, vol.90
, pp. 721-729
-
-
Sheffner, A.L.1
Medler, E.M.2
Jacobs, L.W.3
-
86
-
-
0017111053
-
A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
-
Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 1976; 09[5-6]: 393-6.
-
(1976)
Eur J Clin Pharmacol
, vol.9
, Issue.5-6
, pp. 393-396
-
-
Grassi, C.1
Morandini, G.C.2
-
87
-
-
0028040727
-
Orally administered Nacetylcysteine may improve general well-being in patients with mild chronic bronchitis
-
Hansen NC, Skriver A, Brorsen-Riis L et al. Orally administered Nacetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88[7]: 531-535.
-
(1994)
Respir Med
, vol.88
, Issue.7
, pp. 531-535
-
-
Hansen, N.C.1
Skriver, A.2
Brorsen-Riis, L.3
-
88
-
-
0037718518
-
N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease
-
Gerrits CM, Herings RM, Leufkens HG, et al. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003; 21[5]: 795-798.
-
(2003)
Eur Respir J
, vol.21
, Issue.5
, pp. 795-798
-
-
Gerrits, C.M.1
Herings, R.M.2
Leufkens, H.G.3
-
89
-
-
13144274594
-
Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease
-
Black PN, Morgan-Day A, McMillan TE, et al. Randomised, controlled trial of N-acetylcysteine for treatment of acute exacerbations of chronic obstructive pulmonary disease. BMC Pulm Med 2004; 4[1]: 13.
-
(2004)
BMC Pulm Med
, vol.4
, Issue.1
, pp. 13
-
-
Black, P.N.1
Morgan-Day, A.2
McMillan, T.E.3
-
90
-
-
20944433417
-
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease [Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS]: A randomised placebo-controlled trial
-
Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease [Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS]: a randomised placebo-controlled trial. Lancet 2005; 365[9470]: 1552-1560.
-
(2005)
Lancet
, vol.365
, Issue.9470
, pp. 1552-1560
-
-
Decramer, M.1
Rutten-Van, M.M.2
Dekhuijzen, P.N.3
-
91
-
-
0023096396
-
No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid
-
Cotgreave IA, Eklund A, Larsson K, et al. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 70[2]: 73-77.
-
(1987)
Eur J Respir Dis
, vol.70
, Issue.2
, pp. 73-77
-
-
Cotgreave, I.A.1
Eklund, A.2
Larsson, K.3
-
92
-
-
0026029981
-
Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine
-
Bridgeman MM, Marsden M, MacNee W, et al. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 1991; 46[1]: 39-42.
-
(1991)
Thorax
, vol.46
, Issue.1
, pp. 39-42
-
-
Bridgeman, M.M.1
Marsden, M.2
Macnee, W.3
-
93
-
-
33645229803
-
High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis
-
Tirouvanziam R, Conrad CK, Bottiglieri T, et al. High-dose oral Nacetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103[12]: 4628-4633.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, Issue.12
, pp. 4628-4633
-
-
Tirouvanziam, R.1
Conrad, C.K.2
Bottiglieri, T.3
-
94
-
-
0025647882
-
Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum
-
Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990; 87[23]: 9188-92.
-
(1990)
Proc Natl Acad Sci USA
, vol.87
, Issue.23
, pp. 9188-9192
-
-
Shak, S.1
Capon, D.J.2
Hellmiss, R.3
-
95
-
-
0030027655
-
In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis
-
Shah PL, Scott SF, Knight RA, et al. In vivo effects of recombinant human DNase I on sputum in patients with cystic fibrosis. Thorax 1996; 51[2]: 119-25.
-
(1996)
Thorax
, vol.51
, Issue.2
, pp. 119-125
-
-
Shah, P.L.1
Scott, S.F.2
Knight, R.A.3
-
96
-
-
0026602608
-
Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study
-
Aitken ML, Burke W, McDonald G, et al. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study. JAMA 1992; 267[14]: 1947-51.
-
(1992)
JAMA
, vol.267
, Issue.14
, pp. 1947-1951
-
-
Aitken, M.L.1
Burke, W.2
McDonald, G.3
-
97
-
-
0028129568
-
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
-
Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994; 331: 637-42.
-
(1994)
N Engl J Med
, vol.331
, pp. 637-642
-
-
Fuchs, H.J.1
Borowitz, D.S.2
Christiansen, D.H.3
-
98
-
-
0029921953
-
Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group
-
McCoy K, Hamilton S, Johnson C. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group. Chest 1996; 110[4]: 889-5.
-
(1996)
Chest
, vol.110
, Issue.4
, pp. 889-895
-
-
McCoy, K.1
Hamilton, S.2
Johnson, C.3
-
99
-
-
8944262191
-
Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations
-
Wilmott RW, Amin RS, Colin AA et al. Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations. Am J Respir Crit Care Med 1996; 153[6 Pt 1]: 1914-7.
-
(1996)
Am J Respir Crit Care Med
, vol.153
, Issue.6 Pt 1
, pp. 1914-1917
-
-
Wilmott, R.W.1
Amin, R.S.2
Colin, A.A.3
-
100
-
-
0035666058
-
A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities
-
Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-20.
-
(2001)
J Pediatr
, vol.139
, pp. 813-820
-
-
Quan, J.M.1
Tiddens, H.A.2
Sy, J.P.3
-
102
-
-
79953287790
-
The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis
-
Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011; 37[4]: 806-12.
-
(2011)
Eur Respir J
, vol.37
, Issue.4
, pp. 806-812
-
-
Amin, R.1
Subbarao, P.2
Lou, W.3
-
103
-
-
10344250594
-
Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis
-
Paul K, Rietschel E, Ballmann M et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169[6]: 719-25.
-
(2004)
Am J Respir Crit Care Med
, vol.169
, Issue.6
, pp. 719-725
-
-
Paul, K.1
Rietschel, E.2
Ballmann, M.3
-
104
-
-
84856421613
-
New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
-
Waters V, New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas. Curr Pharm Des 2012; 18(5): 696-725.
-
(2012)
Curr Pharm Des
, vol.18
, Issue.5
, pp. 696-725
-
-
Waters, V.1
-
105
-
-
84856455714
-
New developments in inhaled antibiotics for the treatment of
-
Hofmann T. New developments in inhaled antibiotics for the treatment of Pseudomonas aeruginosa. 2012; 18(5): 683-95.
-
(2012)
Pseudomonas Aeruginosa
, vol.18
, Issue.5
, pp. 683-695
-
-
Hofmann, T.1
-
106
-
-
70350449606
-
The approach to Pseudomonas aeruginosa in cystic fibrosis
-
Bendiak GN, Ratjen F. The approach to Pseudomonas aeruginosa in cystic fibrosis. Semin Respir Crit Care Med 2009; 30[5]: 587-95.
-
(2009)
Semin Respir Crit Care Med
, vol.30
, Issue.5
, pp. 587-595
-
-
Bendiak, G.N.1
Ratjen, F.2
-
107
-
-
0028920643
-
Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface
-
Imundo L, Barasch J, Prince A, et al. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci USA 1995; 92: 3019-23.
-
(1995)
Proc Natl Acad Sci USA
, vol.92
, pp. 3019-3023
-
-
Imundo, L.1
Barasch, J.2
Prince, A.3
-
108
-
-
0030021470
-
Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections
-
Pier GB, Grout M, Zaidi TS, et al. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 1996; 271: 64-7.
-
(1996)
Science
, vol.271
, pp. 64-67
-
-
Pier, G.B.1
Grout, M.2
Zaidi, T.S.3
-
109
-
-
0029870085
-
Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid
-
Smith JJ, Travis SM, Greenberg EP, et al. Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 1996; 85: 229-36.
-
(1996)
Cell
, vol.85
, pp. 229-236
-
-
Smith, J.J.1
Travis, S.M.2
Greenberg, E.P.3
-
110
-
-
60249088927
-
Respiratory pathogens in children with and without respiratory symptoms
-
van der Zalm MM, van Ewijk BE, Wilbrink B, et al. Respiratory pathogens in children with and without respiratory symptoms. J Pediatr 2009; 154[3]: 396-400
-
(2009)
J Pediatr
, vol.154
, Issue.3
, pp. 396-400
-
-
van der Zalm, M.M.1
van Ewijk, B.E.2
Wilbrink, B.3
-
111
-
-
0026831341
-
Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis
-
Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12[3]: 158-61.
-
(1992)
Pediatr Pulmonol
, vol.12
, Issue.3
, pp. 158-161
-
-
Henry, R.L.1
Mellis, C.M.2
Petrovic, L.3
-
112
-
-
0031661390
-
Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis
-
Sep
-
Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998 Sep; 53[9]: 732-7.
-
(1998)
Thorax
, vol.53
, Issue.9
, pp. 732-737
-
-
Ballmann, M.1
Rabsch, P.2
von der Hardt, H.3
-
113
-
-
0142043977
-
Pathophysiology and management of pulmonary infections in cystic fibrosis
-
Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
-
(2003)
Am J Respir Crit Care Med
, vol.168
, pp. 918-951
-
-
Gibson, R.L.1
Burns, J.L.2
Ramsey, B.W.3
-
114
-
-
33750302487
-
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis
-
Nov
-
Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006 Nov; 12[6]: 428-32.
-
(2006)
Curr Opin Pulm Med
, vol.12
, Issue.6
, pp. 428-432
-
-
Ratjen, F.1
-
115
-
-
0025136898
-
Mucoid Pseudomonas aeruginosa in cystic fibrosis: Mutations in the muc loci affect transcription of the algR and algD genes in response to environmental stimuli
-
Deretic V, Govan JR, Konyecsni WM, et al. Mucoid Pseudomonas aeruginosa in cystic fibrosis: mutations in the muc loci affect transcription of the algR and algD genes in response to environmental stimuli. Mol Microbiol 1990; 4: 189-96.
-
(1990)
Mol Microbiol
, vol.4
, pp. 189-196
-
-
Deretic, V.1
Govan, J.R.2
Konyecsni, W.M.3
-
116
-
-
0034641962
-
Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms
-
Singh PK, Schaefer AL, Parsek MR, et al. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000; 407: 762-4.
-
(2000)
Nature
, vol.407
, pp. 762-764
-
-
Singh, P.K.1
Schaefer, A.L.2
Parsek, M.R.3
-
117
-
-
0022503266
-
Antibiotic activity in sputum
-
Levy J. Antibiotic activity in sputum. J Pediatr 1986; 108: 841-846.
-
(1986)
J Pediatr
, vol.108
, pp. 841-846
-
-
Levy, J.1
-
118
-
-
0034685940
-
High frequency of hypermutable Pseudomonas aeruginosa n cystic fibrosis lung infection
-
Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa n cystic fibrosis lung infection. Science 2000; 288: 1251-4.
-
(2000)
Science
, vol.288
, pp. 1251-1254
-
-
Oliver, A.1
Canton, R.2
Campo, P.3
-
120
-
-
2642712510
-
Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis
-
Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled double-blind randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonisation in cystic fibrosis. Pediatr Pulmonol 1998; 26: 88-92.
-
(1998)
Pediatr Pulmonol
, vol.26
, pp. 88-92
-
-
Wiesemann, H.G.1
Steinkamp, G.2
Ratjen, F.3
-
121
-
-
0035934545
-
Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis
-
Ratjen F, Döring G, Nikolaizik W. Eradication of Pseudomonas aeruginosa with inhaled tobramycin in patients with cystic fibrosis. Lancet 2001; 358: 983-4.
-
(2001)
Lancet
, vol.358
, pp. 983-984
-
-
Ratjen, F.1
Döring, G.2
Nikolaizik, W.3
-
122
-
-
0025868478
-
Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment
-
Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation by early treatment. Lancet 1991; 338: 725-6.
-
(1991)
Lancet
, vol.338
, pp. 725-726
-
-
Valerius, N.H.1
Koch, C.2
Hoiby, N.3
-
123
-
-
0034785372
-
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization
-
Munck A, Bonacorsi S, Mariani-Kurkdjian P, et al. Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol 2001; 32: 288-92.
-
(2001)
Pediatr Pulmonol
, vol.32
, pp. 288-292
-
-
Munck, A.1
Bonacorsi, S.2
Mariani-Kurkdjian, P.3
-
124
-
-
0037445216
-
Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
-
Gibson RL, Emerson J, McNamara S, et al. Cystic Fibrosis Therapeutics Development Network Study Group. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-9.
-
(2003)
Am J Respir Crit Care Med
, vol.167
, pp. 841-849
-
-
Gibson, R.L.1
Emerson, J.2
McNamara, S.3
-
125
-
-
77950914953
-
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE trial
-
Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65[4]: 286-91.
-
(2010)
Thorax
, vol.65
, Issue.4
, pp. 286-291
-
-
Ratjen, F.1
Munck, A.2
Kho, P.3
-
126
-
-
70449687936
-
Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: A review
-
Ratjen F, Brockhaus F, Angyalosi G. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J Cyst Fibros 2009; 8[6]: 361-9.
-
(2009)
J Cyst Fibros
, vol.8
, Issue.6
, pp. 361-369
-
-
Ratjen, F.1
Brockhaus, F.2
Angyalosi, G.3
-
127
-
-
79955925867
-
The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis
-
Feb
-
Amin R, Lam M, Dupuis A, et al. The effect of early Pseudomonas aeruginosa treatment on lung function in pediatric cystic fibrosis. Pediatr Pulmonol 2011 Feb 18.
-
(2011)
Pediatr Pulmonol
, pp. 18
-
-
Amin, R.1
Lam, M.2
Dupuis, A.3
-
128
-
-
80052511405
-
Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis
-
Early Pseudomonas Infection Control (EPIC) Investigators
-
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW; Early Pseudomonas Infection Control (EPIC) Investigators. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165(9): 847-56.
-
(2011)
Arch Pediatr Adolesc Med
, vol.165
, Issue.9
, pp. 847-856
-
-
Treggiari, M.M.1
Retsch-Bogart, G.2
Mayer-Hamblett, N.3
Khan, U.4
Kulich, M.5
Kronmal, R.6
Williams, J.7
Hiatt, P.8
Gibson, R.L.9
Spencer, T.10
Orenstein, D.11
Chatfield, B.A.12
Froh, D.K.13
Burns, J.L.14
Rosenfeld, M.15
Ramsey, B.W.16
-
129
-
-
84856501596
-
-
http://www.hta.ac.uk/1763.
-
-
-
-
130
-
-
84856495280
-
-
NCT01082367
-
www.clinicaltrials.gov: NCT01082367.
-
-
-
-
131
-
-
55549137086
-
Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis
-
McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178[9]: 921-8.
-
(2008)
Am J Respir Crit Care Med
, vol.178
, Issue.9
, pp. 921-928
-
-
McCoy, K.S.1
Quittner, A.L.2
Oermann, C.M.3
-
132
-
-
65949124667
-
Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
-
Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135[5]: 1223-32.
-
(2009)
Chest
, vol.135
, Issue.5
, pp. 1223-1232
-
-
Retsch-Bogart, G.Z.1
Quittner, A.L.2
Gibson, R.L.3
-
133
-
-
2442526705
-
Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis
-
Moskowitz SM, Foster JM, Emerson J, et al. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004; 42[5]: 1915-22.
-
(2004)
J Clin Microbiol
, vol.42
, Issue.5
, pp. 1915-1922
-
-
Moskowitz, S.M.1
Foster, J.M.2
Emerson, J.3
-
134
-
-
67149133088
-
Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia
-
Ribeiro CM, Hurd H, Wu Y, et al. Azithromycin treatment alters gene expression in inflammatory, lipid metabolism, and cell cycle pathways in well-differentiated human airway epithelia. PLoS One 2009; 4[6]: e5806.
-
(2009)
PLoS One
, vol.4
, Issue.6
-
-
Ribeiro, C.M.1
Hurd, H.2
Wu, Y.3
-
135
-
-
0035991529
-
Use of modulators of airways inflammation in patients with CF
-
Ren CL. Use of modulators of airways inflammation in patients with CF. Clin Rev Allergy Immunol 2002; 23[1]: 29-39.
-
(2002)
Clin Rev Allergy Immunol
, vol.23
, Issue.1
, pp. 29-39
-
-
Ren, C.L.1
-
136
-
-
3142580825
-
Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study
-
Hillis GS, Pearson CV, Harding SA, et al. Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: A double-blind, randomized, placebo-controlled study. Am Heart J 2004; 148[1]: 72-9.
-
(2004)
Am Heart J
, vol.148
, Issue.1
, pp. 72-79
-
-
Hillis, G.S.1
Pearson, C.V.2
Harding, S.A.3
-
137
-
-
79251591304
-
A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation
-
Vos R, Vanaudenaerde BM, Verleden SE, et al. A randomised controlled trial of azithromycin to prevent chronic rejection after lung transplantation. Eur Respir J 2011; 37[1]: 164-72.
-
(2011)
Eur Respir J
, vol.37
, Issue.1
, pp. 164-172
-
-
Vos, R.1
Vanaudenaerde, B.M.2
Verleden, S.E.3
-
138
-
-
0036185807
-
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: A randomised trial
-
Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57[3]: 212-216.
-
(2002)
Thorax
, vol.57
, Issue.3
, pp. 212-216
-
-
Wolter, J.1
Seeney, S.2
Bell, S.3
-
139
-
-
0037190575
-
Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial
-
Equi A, Balfour-Lynn IM, Bush A, et al. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002; 360[9338]: 978-984.
-
(2002)
Lancet
, vol.360
, Issue.9338
, pp. 978-984
-
-
Equi, A.1
Balfour-Lynn, I.M.2
Bush, A.3
-
140
-
-
0141816759
-
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial
-
Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290[13]: 1749-1756.
-
(2003)
JAMA
, vol.290
, Issue.13
, pp. 1749-1756
-
-
Saiman, L.1
Marshall, B.C.2
Mayer-Hamblett, N.3
-
141
-
-
33749984264
-
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial
-
Clement A, Tamalet A, Leroux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006; 61[10]: 895-902.
-
(2006)
Thorax
, vol.61
, Issue.10
, pp. 895-902
-
-
Clement, A.1
Tamalet, A.2
Leroux, E.3
-
142
-
-
77951887288
-
Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial
-
Saiman L, Anstead M, Mayer-Hamblett N, et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2010; 303[17]: 1707-15.
-
(2010)
JAMA
, vol.303
, Issue.17
, pp. 1707-1715
-
-
Saiman, L.1
Anstead, M.2
Mayer-Hamblett, N.3
-
143
-
-
84856495278
-
-
NCT01270074
-
www.clinicaltrials,.gov: NCT01270074.
-
-
-
-
144
-
-
28344451370
-
Lower airway inflammation in infants with cystic fibrosis detected by newborn screening
-
Armstrong DS, Hook SM, Jamsen KM, et al. Lower airway inflammation in infants with cystic fibrosis detected by newborn screening. Pediatr Pulmonol 2005; 40: 500-10.
-
(2005)
Pediatr Pulmonol
, vol.40
, pp. 500-510
-
-
Armstrong, D.S.1
Hook, S.M.2
Jamsen, K.M.3
-
145
-
-
0034816052
-
Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Clchannel function
-
Weber AJ, Soong G, Bryan R, et al. Activation of NF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Clchannel function. Am J Physiol Lung Cell Mol Physiol 2001; 281: L71-8.
-
(2001)
Am J Physiol Lung Cell Mol Physiol
, vol.281
-
-
Weber, A.J.1
Soong, G.2
Bryan, R.3
-
146
-
-
0034997191
-
Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines
-
Kube D, Sontich U, Fletcher D, et al. Proinflammatory cytokine responses to P. aeruginosa infection in human airway epithelial cell lines. Am J Physiol Lung Cell Mol Physiol 2001; 280: L493-502.
-
(2001)
Am J Physiol Lung Cell Mol Physiol
, vol.280
-
-
Kube, D.1
Sontich, U.2
Fletcher, D.3
-
147
-
-
0036840478
-
Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis
-
Aldallal N, McNaughton EE, Manzel LJ, et al. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. Am J Respir Crit Care Med 2002; 166[9]: 1248-56.
-
(2002)
Am J Respir Crit Care Med
, vol.166
, Issue.9
, pp. 1248-1256
-
-
Aldallal, N.1
McNaughton, E.E.2
Manzel, L.J.3
-
149
-
-
0033844485
-
Inflammation and infection in naive human cystic fibrosis airway grafts
-
Tirouvanziam R, de Bentzmann S, Hubeau C, et al. Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 2000; 23: 121-7.
-
(2000)
Am J Respir Cell Mol Biol
, vol.23
, pp. 121-127
-
-
Tirouvanziam, R.1
de Bentzmann, S.2
Hubeau, C.3
-
150
-
-
0034999076
-
Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa
-
Hubeau C, Lorenzato M, Couetil JP, et al. Quantitative analysis of inflammatory cells infiltrating the cystic fibrosis airway mucosa. Clin Exp Immunol 2001; 124[1]: 69-76.
-
(2001)
Clin Exp Immunol
, vol.124
, Issue.1
, pp. 69-76
-
-
Hubeau, C.1
Lorenzato, M.2
Couetil, J.P.3
-
152
-
-
0029372481
-
Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis
-
Bonfield TL, Konstan MW, Burfeind P, et al. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 1995; 13: 257-61.
-
(1995)
Am J Respir Cell Mol Biol
, vol.13
, pp. 257-261
-
-
Bonfield, T.L.1
Konstan, M.W.2
Burfeind, P.3
-
153
-
-
39449133330
-
Airway inflammation in cystic fibrosis
-
Elizur A, Cannon CL, Ferkol TW. Airway inflammation in cystic fibrosis. Chest 2008; 133[2]: 489-95.
-
(2008)
Chest
, vol.133
, Issue.2
, pp. 489-495
-
-
Elizur, A.1
Cannon, C.L.2
Ferkol, T.W.3
-
154
-
-
77952974496
-
Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth
-
Stoltz DA, Meyerholz DK, Pezzulo AA, et al. Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med 2010; 2[29]: 29ra31.
-
(2010)
Sci Transl Med
, vol.2
, Issue.29
-
-
Stoltz, D.A.1
Meyerholz, D.K.2
Pezzulo, A.A.3
-
155
-
-
77956379893
-
Disease phenotype of a ferret CFTRknockout model of cystic fibrosis
-
Sun X, Sui H, Fisher JT, et al. Disease phenotype of a ferret CFTRknockout model of cystic fibrosis. J Clin Invest 2010; 120[9]: 3149-60.
-
(2010)
J Clin Invest
, vol.120
, Issue.9
, pp. 3149-3160
-
-
Sun, X.1
Sui, H.2
Fisher, J.T.3
-
156
-
-
9144237586
-
Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
-
Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 1471-1475.
-
(2003)
Am J Respir Crit Care Med
, vol.168
, pp. 1471-1475
-
-
Ordonez, C.L.1
Henig, N.R.2
Mayer-Hamblett, N.3
-
157
-
-
0028969594
-
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
-
Eigen H, Rosenstein BJ, Fitzsimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995, 126: 515-523.
-
(1995)
J Pediatr
, vol.126
, pp. 515-523
-
-
Eigen, H.1
Rosenstein, B.J.2
Fitzsimmons, S.3
-
158
-
-
0034704799
-
Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis
-
Lai HC, FitzSimmons SC, Allen DB et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342: 851-9.
-
(2000)
N Engl J Med
, vol.342
, pp. 851-859
-
-
Lai, H.C.1
Fitzsimmons, S.C.2
Allen, D.B.3
-
159
-
-
35448992094
-
Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: A pilot study
-
Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007; 132[4]: 1212-8.
-
(2007)
Chest
, vol.132
, Issue.4
, pp. 1212-1218
-
-
Dovey, M.1
Aitken, M.L.2
Emerson, J.3
-
160
-
-
33745130682
-
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis
-
Balfour-Lynn IM, Lees B, Hall P, et al. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006; 173[12]: 1356-62.
-
(2006)
Am J Respir Crit Care Med
, vol.173
, Issue.12
, pp. 1356-1362
-
-
Balfour-Lynn, I.M.1
Lees, B.2
Hall, P.3
-
161
-
-
0028914667
-
Effect of high-dose ibuprofen in patients with cystic fibrosis
-
Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995, 332: 848-54.
-
(1995)
N Engl J Med
, vol.332
, pp. 848-854
-
-
Konstan, M.W.1
Byard, P.J.2
Hoppel, C.L.3
-
162
-
-
34548038663
-
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial
-
Lands LC, Milner R, Cantin AM, et al. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151[3]: 249-54.
-
(2007)
J Pediatr
, vol.151
, Issue.3
, pp. 249-254
-
-
Lands, L.C.1
Milner, R.2
Cantin, A.M.3
-
163
-
-
34548023098
-
Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis [at least at the moment]
-
Bush A, Davies J. Non! to non-steroidal anti-inflammatory therapy for inflammatory lung disease in cystic fibrosis [at least at the moment]. J Pediatr 2007; 151[3]: 228-30.
-
(2007)
J Pediatr
, vol.151
, Issue.3
, pp. 228-230
-
-
Bush, A.1
Davies, J.2
|